TCT

WASHINGTON — At TCT 2016, Corindus Vascular Robotics demonstrated a second-generation vascular robotic system for PCI, which recently received 510(k) clearance from the FDA.

WASHINGTON — Among patients with critical limb ischemia, the use of percutaneous catheter-delivered ultrasound and paclitaxel offers ease of use and efficacy in treating all lesion lengths and vessel sizes at any location, according to findings from the PACUS trial presented at TCT 2016.

WASHINGTON — Among patients with peripheral artery disease, a second-generation drug-coated balloon appears to yield positive safety and efficacy outcomes, according to findings from the ENDURE trial presented at TCT 2016.

WASHINGTON — A bioresorbable vascular scaffold did not meet its coprimary endpoint of noninferior late luminal loss or its mechanistic coprimary endpoint of superior vasomotor reactivity vs. an everolimus-eluting stent, according to 3-year results from the ABSORB II trial presented at TCT 2016.

WASHINGTON — Early feasibility studies are reviving device innovation in the United States, and offer several clinical advantages, as well as challenges, for interventional cardiologists, according to a speaker at TCT 2016.

WASHINGTON — In the ILLUMENATE trial, both safety and effectiveness endpoints demonstrated superiority of a drug-coated balloon over percutaneous transluminal angioplasty at 1 year in patients with superficial femoral artery disease, according to data reported at TCT 2016.

WASHINGTON — In the RevElution study, a polymer-free drug-filled stent met the primary endpoint of in-stent late lumen loss at 9 months compared with a drug-eluting stent, and was also linked with positive clinical outcomes, researchers reported at TCT 2016.

WASHINGTON — Although a transcatheter embolic protection device was safe, the primary endpoints of the SENTINEL study were not met, according to a presentation at TCT 2016.

WASHINGTON — In this video, Patrick T. O’Gara, MD, MACC, past president of the American College of Cardiology and director of clinical cardiology and executive medical director, Shapiro Cardiovascular Center, Brigham and Women’s Hospital, discusses embolic protection during transcatheter aortic valve replacement to reduce stroke risk.

WASHINGTON — In this video, Vinod H. Thourani, MD, of Emory University in Atlanta, discusses the effort to decrease stroke after transcatheter aortic valve replacement procedures using an embolic protection device (Sentinel Cerebral Protection System, Claret Medical).